FDA Drafts New Rules for Testing Vaccine Shelf Life and Stability
Published Date: 6/24/2025
Notice
Summary
The FDA just released a draft guide to help drug makers test how long their medicines stay good and safe. This new guide updates old rules and adds advice for tricky products like vaccines and advanced therapies. Drug companies should get ready to follow these clearer, science-backed steps, which could speed up approvals and save money in the long run.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Consolidated Stability Testing Guidance
The FDA released a draft guidance called “Q1 Stability Testing of Drug Substances and Drug Products” that consolidates prior ICH stability guidances Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C (published November 2003; March 1996; May 1997; January 2003; June 2004; and July 1996). The draft guidance outlines stability data expectations to support drug product marketing, marketing authorization applications, and, where applicable, drug master files.
New Guidance for Vaccines and Advanced Therapies
The revision adds stability-related guidance for product categories that were not previously covered, including advanced therapy medicinal products, vaccines, and other complex biological products including combination products. Companies working with these product types now have stability testing guidance included in this draft.
Internationally Harmonized, Flexible Testing Approach
The draft guidance, prepared under the International Council for Harmonisation (ICH), is intended to provide an internationally harmonized approach to conducting and presenting stability testing data. It also states that alternative, scientifically justified approaches may be used when warranted by scientific considerations and the characteristics of the data being evaluated.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-11551, Process Safety Management of Highly Hazardous Chemicals Standard; Extension of the Office of Management and Budget's (OMB) Approval of Information Collection (Paperwork) Requirements
OSHA is asking for public feedback to keep collecting important safety info about handling dangerous chemicals. This extension means companies must keep following the rules without any new costs or changes right now. It helps make sure everyone stays safe while working with hazardous stuff.
Next: 2025-11553, Importer of Controlled Substances Application: Arizona Department of Corrections
The Arizona Department of Corrections wants to officially import certain controlled substances. This means they’ll be able to bring in these drugs legally for their work, following all the rules. If approved, this could affect how they manage medications and security, with no extra costs mentioned yet.